Longitudinal Trajectories of Digital Cognitive Biomarkers for Multiple Sclerosis
ABSTRACT Background Cognitive impairment is one of the most common and debilitating symptoms of relapsing–remitting multiple sclerosis (RRMS). Digital cognitive biomarkers require less time and resources and are rapidly gaining popularity in clinical settings.
Yi Chao Foong+17 more
wiley +1 more source
The impact of consultants' power dynamics on clients' self-efficacy and managerial stress. [PDF]
Lachmi R, Ben-Hador B, Brender-Ilan Y.
europepmc +1 more source
Claustrum Volume Is Reduced in Multiple Sclerosis and Predicts Disability
ABSTRACT Objective The claustrum is a small, thin structure of predominantly gray matter with broad connectivity and enigmatic function. Little is known regarding the impact of claustrum pathology in multiple sclerosis (MS). Methods This study assessed whether claustrum volume was reduced in MS and whether reductions were associated with specific ...
Nicole Shelley+5 more
wiley +1 more source
Understanding Perceptions, Knowledge and Implementation Barriers of Enhanced Recovery After Surgery Among Surgeons and Anesthesiologists. [PDF]
Haseeb A+8 more
europepmc +1 more source
Exploring gender differences in the working lives of UK hospital consultants
L. Jefferson, K. Bloor, K. Spilsbury
semanticscholar +1 more source
Diagnostic Challenge in Frontal Variant Alzheimer's Disease With Low Amyloid‐β PET Retention
ABSTRACT Diagnosing frontal variant Alzheimer's disease (fvAD) is difficult and could be even more difficult when amyloid‐beta (Aβ) PET retention is low. A 63‐year‐old woman presenting with a 3‐year history of apathy and memory impairment showed executive dysfunction, memory impairment, and severe bilateral frontotemporal atrophy on MRI.
Ryosuke Shimasaki+5 more
wiley +1 more source
Psychosocial screening instruments to assist support consultants in patients with cancer. [PDF]
Driessen HPA+4 more
europepmc +1 more source
Phase 1, First‐In‐Human, Single‐/Multiple‐Ascending Dose Study of Iluzanebart in Healthy Volunteers
ABSTRACT Objective To evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of iluzanebart, a fully human monoclonal antibody TREM2 (triggering receptor expressed on myeloid cells 2) agonist, after single‐ (SAD) and multiple‐ascending‐dose (MAD) administration.
Andreas Meier+8 more
wiley +1 more source